Clinical Trial Update: Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage IIIB/IV Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing IV topotecan/docetaxel combination vs docetaxel alone as second-line therapy in advanced non-small cell lung cancer has completed with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Topotecan/docetaxel combination (IV)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Lung Cancer, Non-Small Cell, Non-Small-Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2019-06-24